UN Report: 4.9 Million Under-Five Deaths in 2024 Signals Global Health Crisis

The United Nations’ latest report on child mortality serves as a stark reminder of the unfinished business in global health, revealing that 4.9 million children under the age of five died in 2024. While this figure represents a continuation of a long-term downward trend from the turn of the century, the absolute number remains a significant indictment of global health systems and the pharmaceutical supply chain's inability to reach the most vulnerable populations. For the biotech and pharmaceutical sectors, these statistics are not just a humanitarian concern but a call to action regarding the distribution of life-saving interventions, including vaccines, antibiotics, and nutritional supplements.

Historically, the world has made remarkable strides in reducing under-five mortality. Since 1990, the global under-five mortality rate has dropped by more than 50%, a success largely attributed to mass immunization campaigns, improved sanitation, and the widespread availability of oral rehydration therapy. However, the 2024 data suggests that the pace of progress is slowing, particularly in regions where conflict, climate change, and economic instability have disrupted healthcare infrastructure. The United Nations Inter-agency Group for Child Mortality Estimation (UN IGME) notes that many of these deaths are concentrated in the neonatal period—the first 28 days of life—where interventions require more sophisticated medical care and specialized pharmaceutical products.

“

Since 1990, the global under-five mortality rate has dropped by more than 50%, a success largely attributed to mass immunization campaigns, improved sanitation, and the widespread availability of oral rehydration therapy.

From a pharmaceutical perspective, the leading causes of death—pneumonia, diarrhea, and malaria—are largely preventable or treatable with existing technologies. The challenge lies in the last mile of delivery and the affordability of newer-generation treatments. For instance, while the pneumococcal conjugate vaccine (PCV) has significantly reduced pneumonia deaths in many countries, its rollout in low-income nations remains uneven. Similarly, the introduction of the R21/Matrix-M and RTS,S/AS01 malaria vaccines represents a major biotech breakthrough, yet the scale of production and the logistics of cold-chain storage continue to limit their impact in the hardest-hit regions of Sub-Saharan Africa.

The 2024 report also highlights a growing disparity in survival outcomes based on geography. A child born in Sub-Saharan Africa is still many times more likely to die before their fifth birthday than a child born in a high-income country. This gap presents a complex challenge for the pharmaceutical industry, which must balance the high costs of R&D with the need for low-cost, high-volume production for global health markets. Organizations like Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation are critical intermediaries in this ecosystem, providing the funding and market guarantees necessary to incentivize companies like GSK, Pfizer, and Sanofi to maintain supply for these regions.